|Long-Term Studies of Survival
Feb 12, 2005
HIV has been around for 25 years. The average life expectancy after infection is 17 years. Although HAART has only been around about 8 years it should be possible to draw some conclusions about characteristics that lead to longer lifespans.
There are several huge cohorts of data: MACS, CASCADE.
What studies have looked at this data to answer any of the basic questions?
For example, in people for whom a date of seroconversion is known within a few months, have those who started treatnent within six months of seroconversion lived on average longer than those who did not?
There are studies attempting to look at the effect of early treatment, but the data for this already exists. When will we see it reported?
Response from Dr. Pierone
Hello and thanks for posting.
All that the observational cohorts can do with their data is to see if early treatment appears to lead to lower viral loads and preserved CD4 cells versus those in the cohort that are not treated. Even this would be a stretch for most cohorts because the precise time of seroconversion is rarely known in these observational studies. As for determining differential death dates, not enough mortality events have occurred (thankfully) in the few patients that had known seroconversion dates who were (or were not) treated. These mortality data will eventually be gathered from ongoing cohort studies, but given the low death rates, it will be many years into the future before we know.
R5 and syncitia forming virus
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.